Months af­ter mas­sive Ipsen deal, BAKX Ther­a­peu­tics nets more cash for its 'Thel­ma and Louise' ap­proach to can­cer cell death

BAKX Ther­a­peu­tics emerged from stealth in a big way back in Ju­ly, strik­ing an $852 mil­lion deal with Ipsen for its lead can­cer can­di­date, a small mol­e­cule de­signed to ac­ti­vate the body’s nat­ur­al process for pro­grammed cell death. And Ipsen’s putting a bit more cash in the com­pa­ny’s cof­fers to see that pro­gram in­to the clin­ic.

CEO Sree Kant un­veiled a $25 mil­lion Se­ries A round on Thurs­day, led by AB Mag­ni­tude Ven­tures Group with a hand from Ipsen and Sher­pa Health­care Part­ners. The funds will be used to ad­vance the com­pa­ny’s BAKX ac­ti­va­tor pro­gram, which traces back to pi­o­neer­ing work around apop­to­sis by the Dana-Far­ber Can­cer In­sti­tute’s Loren Walen­sky and Al­bert Ein­stein Col­lege of Med­i­cine’s Evri­pidis Ga­vathi­o­tis.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN